MIR106A-5p upregulation suppresses autophagy and accelerates malignant phenotype in nasopharyngeal carcinoma.
Zhu Q, Zhang Q, Gu M, Zhang K, Xia T, Zhang S, Chen W, Yin H, Yao H, Fan Y, Pan S, Xie H, Liu H, Cheng T, Zhang P, Zhang T, You B, You Y.
Autophagy. 2021 Jul;17(7):1667-1683. doi: 10.1080/15548627.2020.1781368. Epub 2020 Jul 5.
Targeting CPT1A-mediated fatty acid oxidation sensitizes nasopharyngeal carcinoma to radiation therapy.
Tan Z, Xiao L, Tang M, Bai F, Li J, Li L, Shi F, Li N, Li Y, Du Q, Lu J, Weng X, Yi W, Zhang H, Fan J, Zhou J, Gao Q, Onuchic JN, Bode AM, Luo X, Cao Y.
Theranostics. 2018 Mar 22;8(9):2329-2347. doi: 10.7150/thno.21451. eCollection 2018.
Circular RNA circCLASP2 promotes nasopharyngeal carcinoma progression through binding to DHX9 to enhance PCMT1 translation.
Peng M, Zhang S, Wu P, Hou X, Wang D, Ge J, Qu H, Fan C, Zhou Y, Xiang B, Liao Q, Zhou M, Tan M, Li G, Xiong W, Chen P, Zeng Z, Gong Z.
Mol Cancer. 2025 Mar 6;24(1):67. doi: 10.1186/s12943-025-02272-3.
CircCDYL2 bolsters radiotherapy resistance in nasopharyngeal carcinoma by promoting RAD51 translation initiation for enhanced homologous recombination repair.
Qu H, Wang Y, Yan Q, Fan C, Zhang X, Wang D, Guo C, Chen P, Shi L, Liao Q, Zhou M, Wang F, Zeng Z, Xiang B, Xiong W.
J Exp Clin Cancer Res. 2024 Apr 23;43(1):122. doi: 10.1186/s13046-024-03049-0.
Expression of toll-like receptors in non-endemic nasopharyngeal carcinoma.
Ruuskanen M, Leivo I, Minn H, Vahlberg T, Haglund C, Hagström J, Irjala H.
BMC Cancer. 2019 Jun 25;19(1):624. doi: 10.1186/s12885-019-5816-9.
Prognostic implications of EBER and EBV DNA combinations in nasopharyngeal carcinoma in endemic areas.
Li Y, Wu L, Huang Z, Cai S, Xu S, Wang J, Yu Y, Lai J, Hu D, Qiu S.
BMC Oral Health. 2025 Aug 23;25(1):1361. doi: 10.1186/s12903-025-06733-5.
Application of Real-Time Indocyanine Green Fluorescence Imaging in Recurrent Nasopharyngeal Carcinoma Surgery.
Liang T, Hu X, Li J, He Y, Zhu Z, Yang J, Zhang H, Yu C.
Ann Surg Oncol. 2025 Jun 16. doi: 10.1245/s10434-025-17672-4. Online ahead of print.
Nasopharyngeal carcinoma in situ (NPCIS)--pathologic and clinical perspectives.
Pak MW, To KF, Lo YM, Chan LY, Tong JH, Lo KW, van Hasselt CA.
Head Neck. 2002 Nov;24(11):989-95. doi: 10.1002/hed.10161.
Nasopharyngeal carcinoma in situ: two cases of an emerging diagnostic entity.
Cheung F, Pang SW, Hioe F, Cheung KN, Lee A, Yau TK.
Cancer. 1998 Sep 15;83(6):1069-73.
circRNA_0067717 promotes paclitaxel resistance in nasopharyngeal carcinoma by acting as a scaffold for TRIM41 and p53.
Cheng Y, Zhu Y, Xiao M, Zhang Y, Wang Z, Chen H, Cao K.
Cell Oncol (Dordr). 2023 Jun;46(3):677-695. doi: 10.1007/s13402-023-00776-y. Epub 2023 Jan 27.
